BIONXT SOLUTIONS INC - BNXTF STOCK NEWS

BioNxt Solutions has signed a master services agreement (MSA) with a German international contract research, development, and manufacturing organization (CRDMO) to advance its pipeline of oral dissolvable (ODF) drug formulations.

The CRDMO, based in Munich, Germany, offers certified services and manufacturing capabilities across five countries. BioNxt aims to leverage this agreement to progress its proprietary ODF Cladribine dosage form for the multiple sclerosis (MS) market.

Cladribine tablets, already approved in over 75 countries, including by the FDA and EMA, have annual sales exceeding $1 billion. BioNxt plans to file additional patent applications for Cladribine ODF by early 2025, potentially extending patent protection to 2044.

This agreement facilitates BioNxt's regulatory, technical, and laboratory needs, setting the stage for a human comparative bioequivalence study.

BioNxt Solutions announced the closure of the second tranche of its non-brokered private placement, issuing 1,000,000 common shares at $0.27 each, raising $270,000.

The overall offering aims to issue a maximum of 6,000,000 shares to gather up to $1,620,000. Net proceeds will fund research, development, commercialization, and general working capital.

The company paid $21,600 in cash finder's fees and issued 80,000 non-transferable Common Share purchase warrants, exercisable at $0.36 per share for 24 months.

Securities issued are subject to a statutory hold period of four months plus a day.

BioNxt Solutions announces advancements in its Cladribine program, including upcoming human comparative bioavailability studies in Europe. The company is developing a proprietary ODF Cladribine dosage form for the MS market, with significant market potential. Additionally, BioNxt is conducting a non-brokered private placement to fund research, development, and commercialization programs.

BioNxt Solutions Inc. is progressing towards human comparative bioavailability studies after successful toxicity and pharmacokinetic studies. The company's Cladribine dosage form targets the MS market, with positive animal study results and upcoming human trials. BioNxt aims to tap into the growing global Multiple Sclerosis drug market, with potential patent protection until 2044.

BioNxt Solutions Inc. completes a successful comparative pharmacokinetic study for its Cladribine oral dissolvable film product for Multiple Sclerosis treatment, demonstrating rapid absorption and systemic exposure comparable to the reference drug. The results pave the way for further development and expansion into high-value drug formulations. BioNxt aims to capitalize on the growing market for MS drugs, with the potential to tap into a market expected to reach USD 41 billion by 2033.

BioNxt Solutions Inc. completes a comparative pharmacokinetic study for its Cladribine product for Multiple Sclerosis treatment, following successful toxicity study results. The company is developing a proprietary ODF Cladribine dosage form for the MS market, targeting a significant global market with potential revenue growth. BioNxt accelerates its Cladribine program with GMP product development and patent applications, positioning itself for future market expansion.

BioNxt Solutions Inc. announces the finalization of a settlement agreement with a creditor to settle $282,415 in debt through the issuance of common shares and a cash payment.

BioNxt Solutions Inc. reports successful completion of a toxicity study for its oral dissolvable film-based Cladribine product for Multiple Sclerosis treatment. The study showed positive results in all participants with no indications of toxicity. The company is developing a proprietary hybrid-generic ODF Cladribine dosage form for the MS market, with Cladribine tablets already approved for use in over 75 countries. The global MS drug market is expected to reach USD 41 billion by 2033. BioNxt has filed provisional patent applications and plans for GMP product development and batch production in 2024.

BioNxt Solutions Inc. has successfully closed the final tranche of its non-brokered private placement, raising gross proceeds of $288,000. The company intends to use the net proceeds to fund drug development, commercialization programs, and general working capital purposes. The Offering, totaling 2,920,000 Units, has been closed, and all securities issued are subject to a statutory hold period. The news release emphasizes the use of proceeds and the statutory hold period for the securities.